Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions

Not Recruiting

Trial ID: NCT01657942


The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.

Official Title

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions

Stanford Investigator(s)

Geoffrey Sonn
Geoffrey Sonn

Associate Professor of Urology and, by courtesy, of Radiology (Body MRI)


Inclusion Criteria

   - Biopsy proven adenocarcinoma of the prostate (using a IMAGE-guided 14+ core mapping
   biopsy), and targeted cores as needed obtained up to 6 months prior to scheduled

   - Patient with intermediate risk, early-stage organ-confined prostate cancer (T1a up to
   T2b, N0, M0) and voluntarily chooses ExAblate thermal ablation as the non-invasive
   treatment, who may currently be on watchful waiting or active surveillance and not in
   need of imminent radical therapy.

   - Patient with PSA less than or equal to 20 ng/mL

   - Gleason score 7 (4 + 3 or 3 + 4), based on mapping prostate biopsy, with no more than
   15mm cancer in maximal linear dimension in any single core

   - Single hemilateral index Gleason 7 lesion, identified in the prostate based on biopsy
   mapping with supporting MRI; may have secondary Gleason 6 lesion on ipsilateral or
   contralateral side confirmed with biopsy and/or MRI

Exclusion Criteria

   - Contraindications to MRI

   - History of orchiectomy, PCa-specific chemotherapy, brachytherapy, cryotherapy,
   Photodynamic therapy or radical prostatectomy for treatment of prostate cancer; any
   prior radiation therapy to the pelvis for prostate cancer or any other malignancy

   - Patient under medications that can affect PSA for the last 3 months prior to MRgFUS
   treatment (Androgen Deprivation Treatment; alpha reductase inhibitors)

   - Individuals who are not able or willing to tolerate the required prolonged stationary
   supine position during treatment (approximately 3 hrs. sonication time)

   - Any rectal pathology, anomaly or previous treatment, which could change acoustic
   properties of rectal wall or prevent safe probe insertion (e.g., stenosis, fibrosis,
   inflammatory bowel disease, etc.)

   - Evidence of distant prostate cancer, i.e., including lymph nodes and/or metastasis of
   cancer on imaging

   - Bladder cancer

   - Urethral stricture/bladder neck contracture

   - Prostatitis NIH categories I, II and III

   - Implant near (<1 cm) the prostate


device: ExAblate MR Guided Focused Ultrasound

device: ExAblate MR Guided Focused Ultrasound

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.